GlassScriptPhysician profile
Adrian I Anthony
NPI 1376084632
$27,767.55
in general payments reported to CMS, 2019-2025
28 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $4,166 · 2023: $2,974 · 2024: $5,355 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $6,650 · Travel and Lodging: $6,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,204.86 |
| Consulting Fee | $6,650.00 |
| Travel and Lodging | $6,630.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $10,276.10 | 2022-2025 | Sprint Pns System |
| Abbott Laboratories | $6,337.23 | 2022-2025 | Proclaim, Eterna |
| Saluda Medical Americas, INC. | $3,665.20 | 2023-2025 | Evoke, Evoke Scs |
| Bioventus LLC | $1,467.59 | 2023-2025 | Stimrouter Implantable Kit, Durolane, Stimtrial Surgical Kit |
| Curonix LLC | $857.42 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mml US, INC. | $827.79 | 2024-2025 | Reactiv8 |
| Nevro Corp. | $825.57 | 2022-2024 | Senza |
| Medtronic, INC. | $556.97 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Abbvie INC. | $510.36 | 2023-2025 | Ubrelvy, Qulipta |
| Collegium Pharmaceutical, INC. | $453.54 | 2022-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $372.46 | 2021-2025 | Intracept |
| Vertos Medical, INC. | $351.73 | 2024 | Mild Device Kit |
| Stryker Corporation | $337.91 | 2023-2025 | Spinejack, Optablate |
| Nalu Medical, INC. | $134.95 | 2023 | Nalu Neurostimulation System |
| Ipsen Biopharmaceuticals, INC | $127.78 | 2023-2025 | Dysport |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $125.38 | 2024 | Painteq |
| Vertex Pharmaceuticals Incorporated | $106.55 | 2024-2025 | |
| Pfizer INC. | $96.63 | 2023-2024 | |
| Lilly USA, LLC | $81.32 | 2022-2023 | Reyvow, Emgality |
| Merz Pharmaceuticals, LLC | $59.44 | 2024-2025 | Xeomin |
| Averitas Pharma INC. | $40.31 | 2023-2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.82 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.81 | 2024 | Horizant |
| Avanos Medical | $22.90 | 2024 | Genvisc 850 Sodium Hyaluronate |
| Globus Medical, INC. | $21.42 | 2025 | Senza |
| Stimwave Technologies Incorporated | $20.34 | 2022 | |
| Si-Bone, INC. | $15.15 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.